AstraZeneca's Triple Combination Regimen Receives NMPA's Approval as the Maintenance Treatment for COPD in China
Shots:
- The approval follows PR designation and is based on P-III KRONOS study assessing budesonide/glycopyrronium/formoterol fumarate vs Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate- demonstrated significant improvement in FEV1
- The approval marks the first NMPA approval for a fixed-dose triple-combination regimen in a pressurized metered-dose inhaler device which utilizes Aerosphere delivery technology
- Breztri Aerosphere is an approved triple combination therapy in Japan and is under regulatory review in the US & EU. The triple combination regimen is k/a PT010 outside of China
Click here to read full press release/ article
Ref: AstraZeneca | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com